following a full submission assessed under the end of life and ultra-orphan processes
idelalisib (Zydelig®) is accepted for use within NHS Scotland.
Indication under review: Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Idelalisib demonstrated clinical activity, measured by overall response rate, in a phase II non-comparative study.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of idelalisib and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice192KB (PDF)
- Medicine name:
- idelalisib (Zydelig)
- SMC ID:
- Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 11 May 2015